Cargando…

Risk Factors for Poor Adherence to Betaferon(®) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome

INTRODUCTION: Adherence to treatment, including early treatment discontinuation, in patients with multiple sclerosis or clinically isolated syndrome can be affected by: treatment tolerability, route of drug administration, patient age, disease duration, comorbidities, medical care, and support from...

Descripción completa

Detalles Bibliográficos
Autores principales: Jernas, Łukasz, Wencel, Jacek, Wiak, Andrzej, Bieniek, Marek, Bartosik-Psujek, Halina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047441/
https://www.ncbi.nlm.nih.gov/pubmed/27695075
http://dx.doi.org/10.1371/journal.pone.0157950
_version_ 1782457414484754432
author Jernas, Łukasz
Wencel, Jacek
Wiak, Andrzej
Bieniek, Marek
Bartosik-Psujek, Halina
author_facet Jernas, Łukasz
Wencel, Jacek
Wiak, Andrzej
Bieniek, Marek
Bartosik-Psujek, Halina
author_sort Jernas, Łukasz
collection PubMed
description INTRODUCTION: Adherence to treatment, including early treatment discontinuation, in patients with multiple sclerosis or clinically isolated syndrome can be affected by: treatment tolerability, route of drug administration, patient age, disease duration, comorbidities, medical care, and support from their caregivers. AIM: This study aimed to identify the risk factors for poor adherence to Betaferon(®) treatment, including early discontinuation and omitting doses. MATERIALS AND METHODS: 852 adult patients treated with Betaferon participated in this 24-month study. All patients were interviewed using the Risk of Drop-out Questionnaire, the Center for Epidemiologic Studies Depression Scale and the Kurtzke Expanded Disability Status Scale. RESULTS: Patients who stopped therapy were younger (p = 0.003) had a higher mean EDSS score (p = 0.022), higher mean number of relapses (p = 0.017), and reported more often fear of injection (p = 0.027) and adverse events (p = 0.007) than those who did not stop treatment. Comparing patients who stopped therapy in the first and the second year, patients who stopped therapy in the first year of treatment more frequently reported flu-like symptoms and fever, and those who stopped therapy in the second year reported—ineffectiveness of treatment and disease progression. Multivariable logistic regression models confirmed that young age, short disease duration, advanced and progressing disease, and poor Betaferon tolerability were related to premature treatment discontinuation. The risk of omitting a dose during therapy was increased in patients who were working or studying, who had more advanced disease or more adverse events, and in patients who received less support from their caregivers. CONCLUSIONS: Several reasons may lead to problems with adherence to Betaferon treatment. Patients at higher risk of discontinuing treatment need to be identified early to make caregivers’ support available to them.
format Online
Article
Text
id pubmed-5047441
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-50474412016-10-27 Risk Factors for Poor Adherence to Betaferon(®) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome Jernas, Łukasz Wencel, Jacek Wiak, Andrzej Bieniek, Marek Bartosik-Psujek, Halina PLoS One Research Article INTRODUCTION: Adherence to treatment, including early treatment discontinuation, in patients with multiple sclerosis or clinically isolated syndrome can be affected by: treatment tolerability, route of drug administration, patient age, disease duration, comorbidities, medical care, and support from their caregivers. AIM: This study aimed to identify the risk factors for poor adherence to Betaferon(®) treatment, including early discontinuation and omitting doses. MATERIALS AND METHODS: 852 adult patients treated with Betaferon participated in this 24-month study. All patients were interviewed using the Risk of Drop-out Questionnaire, the Center for Epidemiologic Studies Depression Scale and the Kurtzke Expanded Disability Status Scale. RESULTS: Patients who stopped therapy were younger (p = 0.003) had a higher mean EDSS score (p = 0.022), higher mean number of relapses (p = 0.017), and reported more often fear of injection (p = 0.027) and adverse events (p = 0.007) than those who did not stop treatment. Comparing patients who stopped therapy in the first and the second year, patients who stopped therapy in the first year of treatment more frequently reported flu-like symptoms and fever, and those who stopped therapy in the second year reported—ineffectiveness of treatment and disease progression. Multivariable logistic regression models confirmed that young age, short disease duration, advanced and progressing disease, and poor Betaferon tolerability were related to premature treatment discontinuation. The risk of omitting a dose during therapy was increased in patients who were working or studying, who had more advanced disease or more adverse events, and in patients who received less support from their caregivers. CONCLUSIONS: Several reasons may lead to problems with adherence to Betaferon treatment. Patients at higher risk of discontinuing treatment need to be identified early to make caregivers’ support available to them. Public Library of Science 2016-10-03 /pmc/articles/PMC5047441/ /pubmed/27695075 http://dx.doi.org/10.1371/journal.pone.0157950 Text en © 2016 Jernas et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Jernas, Łukasz
Wencel, Jacek
Wiak, Andrzej
Bieniek, Marek
Bartosik-Psujek, Halina
Risk Factors for Poor Adherence to Betaferon(®) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome
title Risk Factors for Poor Adherence to Betaferon(®) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome
title_full Risk Factors for Poor Adherence to Betaferon(®) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome
title_fullStr Risk Factors for Poor Adherence to Betaferon(®) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome
title_full_unstemmed Risk Factors for Poor Adherence to Betaferon(®) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome
title_short Risk Factors for Poor Adherence to Betaferon(®) Treatment in Patients with Relapsing-Remitting Multiple Sclerosis or Clinically Isolated Syndrome
title_sort risk factors for poor adherence to betaferon(®) treatment in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047441/
https://www.ncbi.nlm.nih.gov/pubmed/27695075
http://dx.doi.org/10.1371/journal.pone.0157950
work_keys_str_mv AT jernasłukasz riskfactorsforpooradherencetobetaferontreatmentinpatientswithrelapsingremittingmultiplesclerosisorclinicallyisolatedsyndrome
AT wenceljacek riskfactorsforpooradherencetobetaferontreatmentinpatientswithrelapsingremittingmultiplesclerosisorclinicallyisolatedsyndrome
AT wiakandrzej riskfactorsforpooradherencetobetaferontreatmentinpatientswithrelapsingremittingmultiplesclerosisorclinicallyisolatedsyndrome
AT bieniekmarek riskfactorsforpooradherencetobetaferontreatmentinpatientswithrelapsingremittingmultiplesclerosisorclinicallyisolatedsyndrome
AT bartosikpsujekhalina riskfactorsforpooradherencetobetaferontreatmentinpatientswithrelapsingremittingmultiplesclerosisorclinicallyisolatedsyndrome